Operating Segments (Tables)

6 Months Ended

Jun. 30, 2026

Operating Segments [Abstract]

Schedule of Group’s CODM

The Group’s CODM is the Chief Executive Officer of the Company.

		Six Months Ended June 30, 2026
		Drug Development				Online Sales				Quantum Simulation				Total
Revenues
External		$	-			$	284			$	-			$	284
Total			-				284				-				284

Cost of revenues			-				72				-				72
Research and development expenses			1,559				-				16				1,575
Sales, marketing and distribution			-				326				-				326
General and administrative expenses			3,154				22				22				3,198

Segments’ operating loss			4,713				136				38				4,887
Finance expense, net															1,164
Loss														$	6,051

		Six months ended June 30, 2025
		Drug Development				Online Sales				Total
Revenues
External		$	-			$	461			$	461
Total			-			$	461			$	461

Cost of revenues			-				101				101
Research and development expenses			938				-				938
Sales, marketing and distribution			-				491				491
General and administrative expenses			2,070				39				2,109
Other income, net			(465	)			-				(465	)

Segment loss			2,543				170				2,713
Company’s share of losses of company accounted for at equity, net											312
Loss on impairment of loans											5,973
Finance expense, net											414

Loss											9,412

		As of June 30, 2026
		Drug Development				Online Sales				Quantum Technology				Total
Segment assets		$	6,736			$	1,309			$	10,446			$	18,491

Segment liabilities		$	4,732			$	394			$	2,094			$	7,220

		As of December 31, 2025
		Drug Development				Online Sales				Total

Segment Assets		$	6,224			$	1,398			$	7,622
Segment Liabilities		$	2,213			$	262			$	2,475